Adjuvant incorporation in immunoanotherapeutics
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/16
A61K-036/14
A61K-051/00
A61K-039/00
A61K-039/39
A61K-045/06
A61K-038/20
A61K-038/21
A61K-039/002
A61K-039/05
A61K-039/08
A61K-039/12
출원번호
US-0084424
(2013-11-19)
등록번호
US-9439859
(2016-09-13)
발명자
/ 주소
Alexis, Frank
Iannacone, Matteo
Shi, Jinjun
Basto, Pamela
Moseman, Elliott Ashley
von Andrian, Ulrich
Langer, Robert S.
Farokhzad, Omid C.
Tonti, Elena
출원인 / 주소
Massachusetts Institute of Technology
대리인 / 주소
Pabst Patent Group LLP
인용정보
피인용 횟수 :
6인용 특허 :
167
초록▼
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface a
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
대표청구항▼
1. A polymeric particulate composition comprising: nanocarriers formed by self-assembly of a mixture of amphiphilic polymers having a hydrophobic polymer selected from the group consisting of polyanhydrides, polyhydroxy acids, and polyesters at one end and a hydrophilic polymer comprising a polyalky
1. A polymeric particulate composition comprising: nanocarriers formed by self-assembly of a mixture of amphiphilic polymers having a hydrophobic polymer selected from the group consisting of polyanhydrides, polyhydroxy acids, and polyesters at one end and a hydrophilic polymer comprising a polyalkylene oxide at the other end and amphiphilic polymers having at least one moiety bound to the hydrophilic ends of the amphiphilic polymers; andan immunostimulatory agent or MHC Class I, MHC Class II or CD1 presentable polypeptide antigen associated with the surface of the nanocarrier; as the moiety bound to the hydrophilic end of the polymer, or encapsulated within the nanocarrier. 2. The composition of claim 1, comprising MHC Class I, MHC Class II or CD-1 presentable polypeptide antigen as the moiety bound to the hydrophilic end of the amphiphilic polymer. 3. The composition of claim 1, comprising a Toll-Like Receptor (TLR) agonist as an immunostimulatory agent. 4. The composition of claim 3, wherein the TLR agonist is a TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, or TLR-10 agonist. 5. The composition of claim 1, comprising a cytokine as an immunostimulant. 6. The composition of claim 1, wherein the composition enhances T-cell proliferation in a human subject. 7. The composition of claim 1, wherein the composition elicits dendritic cell maturation when administered to a human subject. 8. The composition of claim 2, wherein the nanocarriers comprise two or more different MHC Class I, MHC Class II or CD 1 presentable polypeptide antigens. 9. The composition of claim 1, wherein the composition comprises two or more immunostimulatory agents. 10. The composition of claim 9, wherein the composition comprises two or more Toll-Like Receptor (TLR) agonists. 11. The composition of claim 9, wherein the composition comprises one Toll-Like Receptor (TLR) agonist and one non-TLR agonist. 12. The composition of claim 11, wherein the non-TLR agonist is a moiety that induces signaling through the inflammasome, CD40, or a cytokine receptor. 13. The composition of claim 1, further comprising an agent selected from the group consisting of proteins, peptides, carbohydrates, glycoproteins, glycopeptides, and proteoglycans obtained from inactivated, dead or genetically engineered organisms selected from the group consisting of viruses, fungal, protozoan, and parasitic organisms, and cell extracts. 14. A method comprising: administering to a subject an initial dose of the composition of claim 1; and administering to the subject a first subsequent dose of the composition of claim 1 at a time period after the administration of the initial dose to deliver a therapeutically effective amount. 15. The method of claim 14, wherein the time period is an interval ranging from 1 day to 1 year. 16. The method of claim 14, wherein the first dose of the composition elicits T-cell proliferation in the subject. 17. The method of claim 14, wherein one week after administration of the initial dose the blood concentration of antigen-specific T cells in the subject is at least 10-fold higher than the concentration of T cells recognizing an irrelevant antigen to which the subject has no immunological memory. 18. The method of claim 14, wherein one week after administration of the first subsequent dose the blood concentration of antigen-specific T cells in the subject is at least 10-fold higher. 19. The composition of claim 1, wherein the moiety is present in an amount effective to provide a humoral response to the moieties. 20. The composition of claim 1, wherein the diameter of the nanocarriers is greater than 100 nm. 21. The composition of claim 1, comprising one or more pharmaceutically acceptable excipients selected from the group consisting of solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and lubricants. 22. The composition of claim 19, wherein the composition targets a dendritic cell. 23. The composition of claim 19, wherein the composition does not activate complement. 24. The composition of claim 1, wherein the amphiphilic polymers are the same or different.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (167)
Gerster John F. (Woodbury MN) Crooks Stephen L. (Mahtomedi MN) Lindstrom Kyle J. (Houlton WI), 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines.
Schmitz,Juergen; Dzionek,Andrzej; Buck,David William, Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby.
Arimilli Murty N. ; Cundy Kenneth C. ; Dougherty Joseph P. ; Kim Choung U. ; Oliyai Reza ; Stella Valentino J., Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Mikos Antonios G. (Houston TX) Sarakinos Georgios (Boston MA) Vacanti Joseph P. (Winchester MA) Langer Robert S. (Newton MA) Cima Linda G. (Lexington MA), Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures.
Barrera Denise (Oakdale MN) Langer Robert S. (Newton MA) Lansbury ; Jr. Peter T. (Brookline MA) Vacanti Joseph P. (Winchester MA), Biodegradable polymers for cell transplantation.
Vacanti Joseph P. ; Vacanti Charles A. ; Langer Robert S., Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous struct.
D\Amore Patricia (Brookline MA) Leong Kam W. (Cambridge MA) Langer Robert S. (Somerville MA), Bioerodible articles useful as implants and prostheses having predictable degradation rates.
Skwierczynski Raymond D. ; Phares Kenneth R. ; Miller Richard L. ; Li Zheng Jane ; Jozwiakowski Michael J. ; Busch Terri F., Formulations and methods for treatment of mucosal associated conditions with an immune response modifier.
Dalton,James T.; Miller,Duane D.; Steiner,Mitchell S.; Veverka,Karen A., Halogenated selective androgen receptor modulators and methods of use thereof.
Swain Philip A. ; Schad Victoria C. ; Greenstein Julia L. ; Exley Mark A. ; Fox Barbara S. ; Powers Stephen P. ; Gefter Malcolm L., Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same.
Kedl,Ross M.; Griesgraber,George W.; Zarraga,Isidro Angelo E.; Wightman,Paul D., Immunostimulatory compositions and methods of stimulating an immune response.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
Bengs, Holger; Grande, Jürgen; Schuth, Silke; Böhm, Gitte; Schneller, Arnold; Brunner, Anette, Method for preparing smooth-surface spherical microparticles completely or partially made of at least one water-insoluble linear polysaccharide and microparticles produced according to this method.
Deming, Timothy J.; Yu, Miaoer; Curtin, Scott A.; Hwang, Jungyeon; Wyrsta, Michael D.; Nowak, Andrew; Seidel, Scott W., Methods and compositions for controlled polypeptide synthesis.
Jacobson Stephen C. ; Ramsey J. Michael, Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same.
Horoszewicz Julius S. (Williamsville NY), Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A.; Garimella, Viswanadham; Li, Zhi, Nanoparticles having oligonucleotides attached thereto and uses therefor.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Bischofberger Norbert W. ; Jones Robert J. ; Arimilli Murty N. ; Lin Kuei-Ying ; Louie Michael S. ; McGee Lawrence R. ; Prisbe Ernest J. ; Lee William A. ; Cundy Kenneth C., Nucleotide analogs.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
Fessi Curt (Paris FRX) Devissaguet Jean-Philippe (Neuilly S/Seine FRX) Puisieux Francis (Maisons Alfort MO FRX) Thies Curt (St. Louis MO), Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles.
Cech Thomas R. (Boulder CO) Zaug Arthur J. (Louisville CO) Been Michael D. (Boulder CO), RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods.
Hirosue Sachiko ; Mueller Bernhard G.,CHX ; Langer Robert S. ; Mulligan Richard C., Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids.
Larry Gold ; Michael Willis ; Tad Koch ; Steven Ringquist ; Kirk Jensen ; Brent Atkinson, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.